A 2012 article reported chlamydia trachoma damages the cell wall membranes, and the PARP mechanism for normal cell death (apoptosis)—a hallmark of cancer.  PARP inhibitors are effective in treating fast growing and aggressive tumors that thrive in a low oxygen environment—the tumors most resistant to traditional cancer therapy. PARP inhibitors are being used in breast, ovarian, epithelial ovarian, fallopian tube, and peritoneal cancer; and are being studied in colorectal, prostate, and non-small cell lung cancer, and in melanoma. In 2018, an Israeli company reporting using a PJ34 molecule, in mice, to correct damage in the PARP mechanism, and restore normal apoptosis in pancreatic cancer.

Chlamydia trachoma can inhabit mucosa epithelial cells along the reproductive tract, and spread from the reproductive tract to the fallopian tubes and ovaries. Chlamydia trachoma can inhabit intestinal mucosal epithelial cells; and it is reasonable to believe trachoma can spread from the intestine to the pancreas, which is a low oxygen environment that supports aggressive tumor growth. Reproductive tract, intestinal, and pancreatic cells which are infected with chlamydia trachoma and protected from apoptosis, contribute to the development of cancer.

https://www.israel21c.org/scientists-discover-molecule-that-destroys-pancreatic-cancer-cells/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255666/